专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US08178508B2 Methods of stimulating an immune response against prostate specific antigen 有权
标题翻译：刺激针对前列腺特异性抗原的免疫应答的方法
公开(公告)号：US08178508B2
公开(公告)日：2012-05-15
申请号：US12977660
申请日：2010-12-23
申请人： Jeffrey Schlom , Kwong-Yok Tsang , Sam Zaremba
发明人： Jeffrey Schlom , Kwong-Yok Tsang , Sam Zaremba
IPC分类号： A61K48/00
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K2035/124 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/55522 , A61K2039/55527 , C12N5/0636 , C12N9/6445 , C12N2710/24143 , Y10S435/975
摘要： The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for eliciting an immune response against PSA comprising administering (i) a priming inoculation of a first recombinant virus encoding PSA-OP and (ii) one or more boosting inoculations of a second recombinant virus encoding PSA-OP, wherein the first and second recombinant viruses are from a different genus.
摘要翻译：本发明提供了前列腺特异性抗原寡表位肽（PSA-OP），其可用作预防或治疗前列腺癌和抑制前列腺癌细胞的免疫原，以及PSA特异性细胞毒性T的建立和表征细胞线。特别地，本发明提供了引发针对PSA的免疫应答的方法，包括施用（i）编码PSA-OP的第一重组病毒的引发接种和（ii）编码PSA-OP的第二重组病毒的一种或多种加强接种，其中所述第一和第二重组病毒来自不同属。

12. 发明申请

US20110165117A1 IMMUNOGENIC PEPTIDES AND METHODS OF USE 有权
标题翻译：免疫原性和使用方法
公开(公告)号：US20110165117A1
公开(公告)日：2011-07-07
申请号：US13025094
申请日：2011-02-10
申请人： Jeffrey Schlom , Kwong-Yok Tsang , Ira H. Pastan
发明人： Jeffrey Schlom , Kwong-Yok Tsang , Ira H. Pastan
IPC分类号： A61K38/21 , A61K38/20 , A61P35/00 , A61K39/00 , A61K35/12 , C12N7/01 , C12N5/10 , C12N5/02 , C12N15/63 , A61K38/00 , A61K31/7088 , C07K14/435 , C07H21/04
CPC分类号： C07K14/4748 , A61K38/08 , A61K39/0011 , C07K14/82 , C12N2799/023 , C12N2800/00 , G01N2333/70517
摘要： The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described.
摘要翻译： PAGE4基因在生殖组织中表达，并在生殖癌中表达，如前列腺癌，子宫癌和睾丸癌。本文公开了免疫原性PAGE4多肽，以及编码免疫原性PAGE4多肽的核酸，包括这些多核苷酸的载体和用这些载体转化的宿主细胞。这些多肽，多核苷酸，载体和宿主细胞可用于诱导对PAGE4的免疫应答。还描述了检测PAGE4的诊断方法。

13. 发明申请

US20100303720A1 VARIANTS OF HUMANIZED ANTI-CARCINOMA MAb CC49 有权
标题翻译：人类抗癌药物CARB CC49的变种
公开(公告)号：US20100303720A1
公开(公告)日：2010-12-02
申请号：US12819920
申请日：2010-06-21
申请人： Syed V.S. Kashmiri , Eduardo A. Padlan , Jeffrey Schlom
发明人： Syed V.S. Kashmiri , Eduardo A. Padlan , Jeffrey Schlom
IPC分类号： A61K51/10 , A61K39/395 , A61P35/00
CPC分类号： A61K49/0002 , A61K38/00 , A61K51/1045 , A61K2039/505 , C07K16/30 , C07K16/3046 , C07K16/4208 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2799/026 , G01N33/5743
摘要： The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity DeterminingRegions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.
摘要翻译：本发明针对具有最小鼠含量的CC49单克隆抗体的小鼠 - 人嵌合变体。本发明的第一方面提供了存在CC49的全部六（三个重链和三个轻链）互补决定区（CDR）的人源化单克隆抗体（HuCC49）的CDR变体。本发明的第二方面提供了仅存在来自CC49的至少一个CDR的特异性确定区（SDR）的人源化单克隆抗体（HuCC49）的SDR变体。本发明还涉及制备使用变体的变体和治疗方法的生物技术方法。

14. 发明授权

US07247615B2 Peptide agonists of prostate-specific antigen and uses therefor 有权
标题翻译：前列腺特异性抗原肽激动剂及其用途
公开(公告)号：US07247615B2
公开(公告)日：2007-07-24
申请号：US10497003
申请日：2002-11-26
申请人： Jeffrey Schlom , Kwong-yok Tsang
发明人： Jeffrey Schlom , Kwong-yok Tsang
IPC分类号： A61K38/08 , C12P21/02 , C12N1/21 , C12N1/19 , C12N15/63 , C12N5/10 , C07K7/06 , C07H21/04
CPC分类号： C12N9/6445 , A61K38/00
摘要： This invention relates to isolated peptides comprising agonist epitopes of prostate-specific antigen (PSA). In various aspects, the invention relates to peptides comprising agonist epitopes of the PSA-3 cytotoxic T lymphocyte epitope, and nucleic acids encoding peptides that comprise PSA-3 agonist epitopes. Also related are probes, primers, and vectors comprising these nucleic acids, as well as host cells comprising these vectors, and antibodies that bind to the PSA-3 agonist peptides. This invention further relates to diagnostic reagents and methods utilizing the disclosed nucleic acids or antibodies. The invention also relates to pharmaceutical compositions comprising the nucleic acids, host cells, and peptides of the invention, as well as methods of treatment or prevention of prostate cancer employing such compositions, for example, for peptide-mediated, cell-mediated, and vector-mediated immunotherapies.
摘要翻译：本发明涉及包含前列腺特异性抗原（PSA）的激动剂表位的分离的肽。在各个方面，本发明涉及包含PSA-3细胞毒性T淋巴细胞表位的激动剂表位的肽以及编码包含PSA-3激动剂表位的肽的核酸。还涉及包含这些核酸的探针，引物和载体，以及包含这些载体的宿主细胞，以及结合PSA-3激动剂肽的抗体。本发明还涉及利用所公开的核酸或抗体的诊断试剂和方法。本发明还涉及包含本发明的核酸，宿主细胞和肽的药物组合物，以及使用这种组合物治疗或预防前列腺癌的方法，例如肽介导的，细胞介导的和载体的介导的免疫治疗。

15. 发明申请

US20070110718A1 System for treating and preventing breast cancer 有权
标题翻译：用于治疗和预防乳腺癌的系统
公开(公告)号：US20070110718A1
公开(公告)日：2007-05-17
申请号：US10579007
申请日：2004-11-12
申请人： Dennis Panicali , Gail Mazzara , Linda Gritz , Jeffrey Schlom , Kwong-Yok Tsang , James Hodge
发明人： Dennis Panicali , Gail Mazzara , Linda Gritz , Jeffrey Schlom , Kwong-Yok Tsang , James Hodge
IPC分类号： A61K48/00
CPC分类号： C12N15/86 , A61K39/0011 , A61K48/005 , A61K2039/53 , A61K2039/545 , A61K2039/55522 , C12N7/00 , C12N2710/24043 , C12N2710/24071 , C12N2710/24143 , C12N2710/24171 , C12N2799/023
摘要： The present invention is directed to a system for treating individuals at risk of or suffering from breast cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains in a foreign nucleic acid encoding at least one breast cancer antigen.
摘要翻译：本发明涉及用于治疗患有或患有乳腺癌的个体的系统。该系统包括向个体施用重组痘病毒，其中痘病毒含有编码至少一种乳腺癌抗原的外源核酸。

16. 发明授权

US06756038B1 Agonist and antagonist peptides of carcinoembryonic antigen (CEA) 有权
标题翻译：癌胚抗原（CEA）的激动剂和拮抗剂肽
公开(公告)号：US06756038B1
公开(公告)日：2004-06-29
申请号：US09529121
申请日：2000-06-13
申请人： Jeffrey Schlom , Elene Barzaga , Sam Zaremba
发明人： Jeffrey Schlom , Elene Barzaga , Sam Zaremba
IPC分类号： A61K3900
CPC分类号： C07K14/70503 , A61K38/00 , A61K39/00 , A61K48/00 , Y10S435/81
摘要： The present invention relates to the preparation and use of peptides that act as agonists and antagonists of human carcinoembryonic antigen (CEA). Agonists of the CEA peptide, CAP1, are disclosed and their utility in enhancing immune responses against CEA demonstrated.
摘要翻译：本发明涉及作为人癌胚抗原（CEA）的激动剂和拮抗剂的肽的制备和用途。公开了CEA肽CAP1的激动剂，并证明了它们在增强针对CEA的免疫应答方面的效用。

17. 发明授权

US6051225A Family of high affinity, modified antibodies for cancer treatment 失效
标题翻译：高亲和力家族，用于癌症治疗的修饰抗体
公开(公告)号：US6051225A
公开(公告)日：2000-04-18
申请号：US40687
申请日：1993-03-31
申请人： Peter S. Mezes , Brian B. Gourlie , Mark W. Rixon , Jeffrey Schlom , Donald A. Kaplan , W. H. Kerr Anderson
发明人： Peter S. Mezes , Brian B. Gourlie , Mark W. Rixon , Jeffrey Schlom , Donald A. Kaplan , W. H. Kerr Anderson
IPC分类号： A61K38/00 , A61K47/48 , A61K51/10 , A61P35/00 , C07K16/30 , C07K16/46 , C12N15/14 , C12P21/08 , A61K39/375
CPC分类号： A61K47/48669 , A61K51/1087 , C07K16/30 , C07K16/462 , A61K2123/00 , A61K38/00 , C07K2317/24 , C07K2319/00
摘要： This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V.sub.H and V.sub.L sequences which mediate TAG-72 binding and (2) human C.sub.H and C.sub.L regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C.sub.H and C.sub.L antibody domains. The nucleotide and amino acid sequences of V.sub.H .alpha.TAG V.sub.H, CC46 V.sub.H, CC49.sub.H, CC83 V.sub.H, and CC92 V.sub.H, and CC49.sub.L, CC83 V.sub.L, and CC92 V.sub.L idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.
摘要翻译：本发明涉及对人类高分子量肿瘤相关唾液酸化糖蛋白抗原（TAG-72）具有高亲和力的嵌合抗体家族。这些抗体具有（1）介导TAG-72结合的高亲和力动物VH和VL序列，（2）人CH和CL区。据认为，由于其人类CH和CL抗体结构域，当向人类患者施用时，它们会产生显着较少的副作用。公开了VHαTAG VH，CC46VH，CC49H，CC83VV和CC92VV和CC49L，CC83VL和CC92VV独特型序列的核苷酸和氨基酸序列，以及体内使用的治疗和诊断测定方法这些嵌合抗体。

18. 发明授权

US09804163B2 Biomarkers for prostate cancer and methods for their detection 有权
公开(公告)号：US09804163B2
公开(公告)日：2017-10-31
申请号：US13814337
申请日：2011-08-05
申请人： Jeffrey Gildersleeve , Christopher Campbell , Oyindasola Oyelaran , James Gulley , Jeffrey Schlom
发明人： Jeffrey Gildersleeve , Christopher Campbell , Oyindasola Oyelaran , James Gulley , Jeffrey Schlom
IPC分类号： A61K39/00 , C07K14/705 , C07K16/00 , C07K16/30 , G01N33/574
CPC分类号： G01N33/57434 , A61K39/0011 , A61K2039/5252 , A61K2039/5256 , A61K2039/545 , A61K2039/55583 , A61K2039/575 , A61K2039/585 , C12N2710/24043 , C12N2710/24143 , G01N33/57469 , G01N2400/02 , G01N2800/52
摘要： The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.

19. 发明授权

US08883448B2 Mutated ras peptides for generation of CD8+ cytotoxic T lymphocytes 有权
标题翻译：用于产生CD8 +细胞毒性T淋巴细胞的突变ras肽
公开(公告)号：US08883448B2
公开(公告)日：2014-11-11
申请号：US12623062
申请日：2009-11-20
申请人： Jeffrey Schlom , Scott Abrams
发明人： Jeffrey Schlom , Scott Abrams
IPC分类号： C12N15/11 , C07H21/04 , C07K14/82 , A61K39/00
CPC分类号： C07K14/82 , A61K39/00
摘要： Mutant ras oncogene peptides may induce specific anti-ras cellular immune responses in vaccinated patients. Moreover, a human CD8+ CTL epitope(s) reflecting a specific point mutation in the K-ras oncogene at codon 12 was identified. The mutant ras peptide has implications for both active and passive immunotherapies in selected carcinoma patients. A nested 10-mer peptide was identified [i.e., ras5-14(Asp12)], which was shown to bind to HLA-A2 and display specific functional capacity for expansion of the in vivo-primed CD8+ CTL precursors.
摘要翻译：突变ras致癌基因肽可能在接种疫苗的患者中诱导特异性抗ras细胞免疫应答。此外，鉴定了在密码子12反映K-ras致癌基因中的特异性点突变的人CD8 + CTL表位。突变型ras肽对所选癌症患者的主动和被动免疫疗法都有影响。鉴定了嵌合的10聚体肽[即ras5-14（Asp12）]，其显示与HLA-A2结合并显示用于体内引发的CD8 + CTL前体扩增的特异功能能力。

20. 发明申请

US20130156813A1 BIOMARKERS FOR PROSTATE CANCER AND METHODS FOR THEIR DETECTION 有权
标题翻译：前列腺癌的生物标志物及其检测方法
公开(公告)号：US20130156813A1
公开(公告)日：2013-06-20
申请号：US13814337
申请日：2011-08-05
申请人： Jeffrey Gildersleeve , Christopher Campbell , Oyindasola Oyelaran , James Gulley , Jeffrey Schlom
发明人： Jeffrey Gildersleeve , Christopher Campbell , Oyindasola Oyelaran , James Gulley , Jeffrey Schlom
IPC分类号： A61K39/00
CPC分类号： G01N33/57434 , A61K39/0011 , A61K2039/5252 , A61K2039/5256 , A61K2039/545 , A61K2039/55583 , A61K2039/575 , A61K2039/585 , C12N2710/24043 , C12N2710/24143 , G01N33/57469 , G01N2400/02 , G01N2800/52
摘要： The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.
摘要翻译：本发明提供了一种用于预测患有癌症的患者中的癌症疫苗的临床应答的方法，用于确定患有癌症疫苗的癌症患者中的癌症疫苗的免疫应答的方法，用于确定该癌症疫苗的方法在患有癌症的患者中的生存期，以及相应的试剂盒，以及用于改善基于病毒的疫苗的功效的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式